US2021023026A1PendingUtilityA1
Use of rasagiline for the treatment of restless legs syndrome
Est. expiryApr 3, 2026(expired)· nominal 20-yr term from priority
A61P 25/08A61K 31/16A61K 31/428A61P 21/00A61P 25/00A61K 2300/00A61K 31/135A61P 25/14A61P 43/00
73
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A pharmaceutical composition comprising in unit dosage form R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof and at least one of pergolide, pramipexole, oxycodone, clonazepam, carbamazepine, gabapentin, valproate, ropinirole or clonidin.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.